biosimilar registration process in Japan

Japan remains one of the most demanding regulatory environments for biosimilars. The PMDA expects clear evidence, aligned datasets, and precise scientific justification before approval is considered.



https://resource.ddregpharma.com/blogs/expanding-to-japans-pharma-market-heres-what-you-need-to-know/



Sponsors often encounter challenges with data localization, language accuracy, reference product selection, and approval timelines.



DDReg supports each stage of the biosimilar registration process in Japan with consultation planning, dossier localization, GQP/GVP documentation, and lifecycle management.